Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
Nia JulianMarch 3, 2020
Facebook0 Twitter Pinterest0 0 Likes
Previous

Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets

Nia JulianMarch 9, 2020
Next

Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio

Nia JulianDecember 17, 2019

© 2020 Solasta Ventures. All Rights Reserved.